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Abstract
The success of combination antiretroviral therapy is limited by the evolutionary escape dynamics of HIV-1. We used Isotonic
Conjunctive Bayesian Networks (I-CBNs), a class of probabilistic graphical models, to describe this process. We employed
partial order constraints among viral resistance mutations, which give rise to a limited set of mutational pathways, and we
modeled phenotypic drug resistance as monotonically increasing along any escape pathway. Using this model, the
individualized genetic barrier (IGB) to each drug is derived as the probability of the virus not acquiring additional mutations
that confer resistance. Drug-specific IGBs were combined to obtain the IGB to an entire regimen, which quantifies the virus’
genetic potential for developing drug resistance under combination therapy. The IGB was tested as a predictor of
therapeutic outcome using between 2,185 and 2,631 treatment change episodes of subtype B infected patients from the
Swiss HIV Cohort Study Database, a large observational cohort. Using logistic regression, significant univariate predictors
included most of the 18 drugs and single-drug IGBs, the IGB to the entire regimen, the expert rules-based genotypic
susceptibility score (GSS), several individual mutations, and the peak viral load before treatment change. In the multivariate
analysis, the only genotype-derived variables that remained significantly associated with virological success were GSS and,
with 10-fold stronger association, IGB to regimen. When predicting suppression of viral load below 400 cps/ml, IGB
outperformed GSS and also improved GSS-containing predictors significantly, but the difference was not significant for
suppression below 50 cps/ml. Thus, the IGB to regimen is a novel data-derived predictor of treatment outcome that has
potential to improve the interpretation of genotypic drug resistance tests.
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Introduction
Despite an increasing arsenal and improved potency of
antiretroviral drugs, the optimal use of combination antiretroviral
therapy against HIV-1 infection remains challenging [1]. Com-
plicating factors include drug interactions and toxicities, adherence
to therapy, and development of drug resistance [2]. Because
genotypic drug resistance testing is performed on a routine basis
today and because mutational patterns are unique for each
patient, treatment choices are, in principle, highly personalized. In
practice, however, it can be difficult to identify an optimal drug
combination for each individual patient due to the combinatorial
complexity of both the set of feasible drug combinations and of
viral mutational patterns.
In addition to controlled clinical trials, analyzing data from
large observational cohort studies is a promising way to identify
predictors of treatment outcome, even if the availability of drugs
and therapeutic strategies change over time [3]. This approach
can be based on modeling the risk of acquiring additional
mutations [4], on estimating future drug options [5], on predicting
the time to virological failure [6,7], or on classifying the regimens
of treatment change episodes (TCEs) as successful versus failing,
depending on the patient’s response to therapy. A TCE consists of
predictor variables including the applied drug combination, viral
genotype, treatment history, demographic and clinical parameters,
and a response variable such as the change in viral load.
HIV-1 genotype has been shown to be a strong predictor of
therapeutic success in retrospective and prospective studies [8–14],
but the large number of mutations complicates prediction. TCE
classification is a noisy, high-dimensional prediction problem with
unobserved confounding factors and sparse data. It has been
addressed by several statistical learning methods [15–25]. Com-
parative studies have emphasized the importance of selection and
representation of features, especially of the viral genotype, over the
choice of the learning algorithm [26–28]. In order to directly
correlate genotype with clinical response, rules-based approaches,
such as the genotypic susceptibility score (GSS) [29–34] and
statistical models [23,26,28] have been proposed, often outcom-
peting human experts [35].
Drug resistance development is driven by viral evolution and
thus models of viral evolutionary escape from drug pressure have
been proposed to improve therapy response prediction [16,22,36].
Specifically, the individualized genetic barrier (IGB) to drug
resistance has been suggested as a predictor of treatment outcome.
The IGB is defined as the probability of the virus not to become
resistant to a certain drug [37–39]. A high IGB means that viral
evolutionary escape from the selective pressure of the drug is
unlikely. Related quantities are the average number of mutations
and the average time to reach drug resistance derived from
simulated HIV-1 evolutionary trajectories on an estimated fitness
landscape [36,40,41]. This approach has been explored for
treatment with zidovudine plus lamivudine and with nelfinavir
[42], but it does not scale to the variety of combination therapies
observed in clinical databases, because sufficient data for
estimating fitness landscapes is available only for a few drug
combinations. Earlier, the term ‘calculated genetic barrier’ has
been used to assess the number of mutations necessary to acquire
specific drug resistance-associated mutations, which were found to
be similar among HIV-1 subtypes [43].
In the present study, we apply a simplified definition of the IGB
which can be computed efficiently for any drug combination based
on a statistical model that captures the order and the dynamics of
accumulating mutations and the associated levels of phenotypic
drug resistance [44]. The IGB to resistance to a certain drug is the
probability that the virus will not accumulate additional mutations
leading to a resistant strain. This drug-specific IGB has been
demonstrated to be a strong predictor of virological response in
two large observational cohort studies [26,28]. Here, we derive a
novel predictor, the IGB to the entire drug combination which
measures the genetic potential for evolutionary escape of the virus
from the selective pressure of combination therapy.
In order to assess the performance of the IGB as a predictor of
treatment outcome, we analyzed TCE data from the Swiss HIV
Cohort Study (SHCS) database, a large, long-term observational,
multi-center, clinical database with integrated results of genotypic
drug resistance tests [45,46]. We identified risk factors of
therapeutic failure and constructed models of treatment outcome
considering as predictors the applied regimen, treatment history,
viral genotype, GSS, drug-specific IGBs, IGB to regimen, and
demographic and clinical variables including patient adherence.
Overall, we found the IGB to the entire regimen to be the
strongest and most significant predictor. Our results demonstrate
that the viral genotype is represented efficiently by the IGB to
regimen, a single, interpretable probability summarizing the
predicted dynamics of viral evolutionary escape.
Results
For each drug, viral evolutionary escape from its selective
pressure was modeled using Isotonic Conjuctive Bayesian
Networks (I-CBNs). In these probabilistic graphical models,
dependencies among mutations are described by a partial order,
which defines the genotype lattice, i.e., the set of genotypes
compatible with the order constraints, and hence the set of
possible mutational escape pathways (Figure 1). To each genotype,
its level of phenotypic drug resistance is associated using isotonic
regression, such that drug resistance is monotonically non-
decreasing along any mutational pathway from the wild type
towards the genotype carrying all mutations. Using cross-sectional
matched genotype-phenotype pairs from the Stanford HIV Drug
Resistance Database, I-CBN models were learned for a total of 18
antiretroviral drugs (Supporting Figures S4, S5, S6, S7, S8, S9,
S10, S11, S12, S13, S14, S15, S16, S17, S18, S19, S20, S21,
Supporting Table S2). Each model includes up to eleven pre-
selected mutations (see Methods).
From the I-CBN models, transition probabilities among
genotypes were derived and the individualized genetic barrier
(IGB) to resistance development to each drug was computed as the
probability of the observed genotype not acquiring additional
mutations that would transform it into a genotypic state predicted
Author Summary
Drug resistance remains a challenge in the management of
HIV-infected patients. The accumulation of mutations
during ongoing viral replication is the origin of drug
resistance development. Understanding this evolutionary
process in a quantitative manner is an important prereq-
uisite for minimizing the risk of resistance development
and for the optimal selection of drug combinations for
each individual patient. We present probabilistic graphical
models for describing the evolution of drug resistance, and
we derive the individualized genetic barrier (IGB), a single
quantity summarizing the genetic potential of the virus for
evolutionary escape from selective drug pressure. The
predictive power of the IGB is demonstrated on a large
well characterized clinical cohort of HIV patients and
compared to classical predictors.
Individualized Genetic Barrier
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to be resistant. For a drug combination, the IGB was obtained as
the sum over all drugs of the regimen of the drug-specific IGBs.
Thus, the IGB to regimen can be regarded as the expected
number of active components in the drug cocktail taking viral
evolutionary escape mechanisms into account. To assess the
predictive power of the IGB in a clinical setting, we analyzed a
large cohort of HIV-1-infected patients and compared the IGB to
several known predictors of therapy response (Figure 2), including
the GSS, obtained from the Stanford HIV Drug Resistance
Database website (HIVdb 6.2.0).
TCEs from the time period 1988–2010 were derived from the
SHCS database (Table 1 and 2) and labeled as either failure or
success (see Methods). Therapy success was defined as viral load
reduction below 50 cps/ml (400 cps/ml) during treatment. We
obtained 2185 (2631) genotype-therapy pairs, including 73%
(63%) failures. The usage of individual drugs and the 30 most
frequent drug combinations are shown in Supporting Figures S2
and S3, respectively. The historical development of drug usage
patterns is reported in Supporting Table S3, where the regimens
are annotated as either being recommended as first-line or
alternative regimens according to current treatment guidelines
[47], or as past first-line or second-line recommended regimens
that are still in use in developing countries or occasionally used if
drug resistant virus is present at baseline or as salvage regimens, or
as regimens that are not in use anymore as first-line regimens but
were before, including those still used under special circumstances,
such as unusual tolerability.
In order to predict the outcome (failure versus success) of each
therapy, we considered applied drugs, demographic and clinical
variables, viral genotype, IGBs to received drugs, and IGB to
regimen (Figure 2, Table S1). Univariate logistic regression
resulted in a total of 50 (44) features that were significantly
associated with therapy outcome (Figure S22). Among the
predictive drugs, the use of ZDV, d4T, 3TC, and NFV were
Figure 1. Schematic illustration of I-CBN model and individualized genetic barrier (IGB). (A) A partially ordered set of three mutations, A,
B, and C, is considered with the two relations A[B and C[B, resulting in two possible escape pathways of the virus, namely A?C?B or
C?A?B. (B) The partial order constraints give rise to the genotype lattice consisting of genotypes 000, 001, 100, 101, and 111 indicated with bold
arrows, where genotypes are encoded as binary strings such that 000 is the wild type1 (no mutations), 100 is defined by mutation A and identified
with fAg, 101 with fA,Cg, etc. The genotype lattice G is shown inside the embedding hypercube f0,1g3^2fA,B,Cg . For each antiretroviral drug,
genotypes are labeled as either susceptible (green) or resistant (red). (C) Genotype lattice isolated from the embedding hypercube. The IGB is the
probability of the virus not reaching a resistant state.
doi:10.1371/journal.pcbi.1003203.g001
Figure 2. Data flow. Matched pairs of viral genotype and drug resistance phenotype from the Stanford HIV Drug Resistance Database (top right)
were used to learn I-CBN models for all drugs separately. The drug-specific individualized genetic barriers (IGBs) are derived from these models. The
IGB to regimen is computed for each genotype-therapy pair in the Swiss HIV Cohort Database and its predictive power is assessed in prediction
models that also account for classical demographic, clinical, and genetic covariates.
doi:10.1371/journal.pcbi.1003203.g002
Individualized Genetic Barrier
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associated with increased risk of therapeutic failure, while ABC,
TDF, FTC, EFV, RTV, LPV/r, ATV, and ATV/r increased the
odds of therapeutic success. Most of the significant amino acid
changes in the viral protease (PR) gene (10I, 30N, 33F, 46I, 54V,
71V, 82A, 84V, 90M) and reverse transcriptase (RT) gene (39A,
41L, 44D, 67N, 74V, 103N, 118I, 123S, 210W, 215Y, 297R) have
been associated with resistance to multiple PR inhibitors (PIs) and
RT inhibitors (RTIs), respectively, and all except PR 30N and RT
123S increased the risk of treatment failure. A higher IGB to any
of 15 (16) individual drugs increased the chance of successful
virological response. The IGB to the entire drug combination and
the GSS were also significant predictors.
In the multivariate analysis, only 12 (14) variables were
significant, nine (ten) of which are indicating the inclusion of
individual drugs in the regimen (Figure 3). The usage of the
nucleoside RTIs (NRTIs) ZDV, ddI, d4T, and 3TC, and of the
PIs APV and SQV, were associated with negative treatment
outcome, whereas the four boosted PIs (i.e., given together with
low-dose RTV to improve their bioavailability) SQV/r, IDV/r,
LPV/r, and ATV/r had positive predictive power. Among the
many genotype-derived predictors, only GSS and IGB to regimen
reached statistical significance at the 1% level in the multivariate
model. For the 50 cps/ml success definition, the odds ratio (OR) of
therapeutic success was ten-fold higher for the IGB (OR 23.6, 95%
confidence interval [CI] 12.21–45.4, pv10{19) as compared to
the GSS (OR 2.1, 95% CI 1.6–2.7, pv10{7), and similarly for
400 cps/ml (IGB OR 25.0, 95% CI 14.7–42.5, pv10{30 versus
GSS OR 1.8, 95% CI 1.5–2.2, pv10{7), indicating that the IGB
provides an effective summary of the risk of treatment failure due
to viral genetic changes. In addition, increased overall maximum
(peak) viral load before treatment remained a significant predictor
of therapy outcome in the multivariate logistic regression model.
For optimal treatment outcome prediction, we also explored the
use of regularized logistic regression models. Specifically, the
elastic net, which combines L1 and L2 regularization was applied
to identify sparse classifiers of therapy outcome. Classifier
performance was evaluated in ROC curves summarized by the
area under the ROC curve (AUC), and analyzed according to the
historical drug usage patterns (Table S3).The competitive models
(high AUC) are only those using all clinical and demographic
Table 1. Characteristics of the numerical predictors in the SHCS database.
50 cps/ml 400 cps/ml
Numerical variables median (IQR) median (IQR)
Age 40 (35–46) 40 (35–46)
Minimum CD4 T cell count (cells/mm3) 108 (40–200) 110 (40–206)
Maximum viral load (log10 copies/ml) 5.17 (4.72–5.63) 5.15 (4.66–5.61)
doi:10.1371/journal.pcbi.1003203.t001
Table 2. Characteristics of the categorical predictors in the SHCS database.
50 cps/ml 400 cps/ml
Categorical variables frequency (%) frequency (%)
Gender female 562 (25.72%) 705 (26.8%)
male 1623 (74.28%) 1926 (73.2%)
AIDS no 1461 (66.86%) 1775 (67.46%)
yes 724 (33.14%) 856 (32.54%)
Transmission group blood 16 (0.73%) 27 (1.03%)
heterosexual 719 (32.91%) 881 (33.49%)
IDU 491 (22.47%) 598 (22.73%)
male homosexual 879 (40.23%) 1033 (39.26%)
mother-to-child 12 (0.55%) 16 (0.61%)
others/unknown 68 (3.12%) 76 (2.88%)
Ethnic Group 9 (0.41%) 10 (0.38%)
asian 41 (1.88%) 58 (2.2%)
black 281 (12.86%) 347 (13.19%)
hispano american 34 (1.56%) 46 (1.75%)
white 1743 (79.77%) 2080 (79.06%)
unknown 77 (3.52%) 90 (3.42%)
Adherence to treatment low 496 (22.7%) 610 (23.19%)
high 1586 (72.59%) 1899 (72.18%)
others/unknown 103 (4.71%) 122 (4.64%)
doi:10.1371/journal.pcbi.1003203.t002
Individualized Genetic Barrier
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variables, mutations, and drugs (Tables S5, S6, Figure 4). When
comparing IGB to GSS as predictors in this setting, we found a
significant advantage of the IGB for 400 cps/ml if all other
features are included in the models (p~0:01, Wilcoxon rank sum
test). Furthermore, the IGB also improves treatment outcome
prediction if added to models that already contain the GSS
(p~0:0002). For 50 cps/ml, we did not find significant differences
in AUC between IGB and GSS when used in prediction models
that included all other covariates, nor did the GSS-containing
model improve upon adding IGB. The significant increase for the
larger dataset with the 400 cps/ml success definition demonstrates
the predictive power of the IGB and indicates that GSS and IGB,
although correlated, contain some orthogonal information, which,
if combined, can further improve treatment outcome prediction.
A B
Figure 3. Multivariate analysis of predictors of response to antiretroviral combination therapy in the SHCS database. Associations
have been tested using a logistic regression model and odds ratios of therapeutic success, defined as viral load reduction below 50 cps/ml (A) and
400 cps/ml (B), are reported together with their 95% confidence intervals on a logarithmic scale. Benjamini-Hochberg-corrected p-values are
represented as black (pv0:001) and grey (pv0:01) symbols. Only predictors with a p-value smaller than 0.01 are included.
doi:10.1371/journal.pcbi.1003203.g003
A B
Figure 4. ROC curves quantifying the performance of elastic net regularized logistic regression models in predicting treatment
outcome, defined as a reduction of viral load below 50 cps/ml (A) and 400 cps/ml (B). The areas under the ROC curves (AUC values) are
reported in Table S5 and Table S6. Prediction models are encoded by the sets of predictors used, where C refers to the demographic and clinical
variables, D refers to drugs, and M to mutations. For example, the model IGB+CDM includes as predictors IGB to regimen, clinical and demographic
predictors, applied drugs, and mutations. The models with all predictors perform significantly better than all other models.
doi:10.1371/journal.pcbi.1003203.g004
Individualized Genetic Barrier
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Discussion
We have comprehensively analyzed factors of therapy outcome
in the SHCS database using univariate, multivariate, and
regularized multivariate logistic regression models. As predictors
of therapeutic success we identified the applied drugs, the GSS,
and as the strongest predictor the IGB to regimen, a novel
predictor derived from viral genotype.
Including genotype information into treatment outcome
prediction is challenging because of the large number of
observed mutations and the complexity of the genotype-
phenotype relationship. Here, we have explored the IGB to
drug resistance as a summary measure of the escape dynamics
of the virus under treatment. The underlying idea of this
modeling approach is that the IGB captures how difficult it is
for the virus to escape from the selective pressure of individual
drugs or from the entire drug combination. This piece of
information is different from assessing the current genotypic or
phenotypic drug resistance state of the virus, as intended, for
example, by the GSS. The IGB makes a prediction about the
expected escape dynamics of the virus population given its
current genetic state.
The computation of the IGB involves an evolutionary model of
genetic progression under selective drug pressure along multiple
mutational pathways and a notion of evolutionary escape, which
was based here on the predicted level of phenotypic drug
resistance. We applied I-CBN models for jointly describing genetic
progression and associated phenotypic change of the virus. In
particular, phenotype predictions are non-linear in the mutations,
which allows for capturing epistatic effects, i.e., the same mutation
can have different effects on the resistance phenotype depending
on the genetic background of the virus (Figure 1). The I-CBN
models were estimated from independent genotype-phenotype
data. Using these models, the complex, high-dimensional,
genotypic data of each virus can be summarized efficiently by
the IGB to resistance to each drug. Thus, rather than modeling
interactions between drugs and individual mutations, the IGB
provides a comprehensive model of drug-genotype interaction.
In the present study, we have extended the concept of the IGB
to the entire regimen in a fashion that allows for computing this
quantity for any drug combination and hence for large clinical
datasets. The IGB to regimen can be regarded as the expected
number of active drugs in the regimen. Assuming independent
effects among drugs, we compute the regimen IGB from the drug
IGBs. These simplifying assumptions are made for computational
feasibility. They present a conceptual limitation of the approach
and more elaborate models are conceivable. In addition, other
variables not included in this study might be important, for
example, pharmacological properties of drug combinations and
host genetic factors. Here, the IGB, a single interpretable quantity,
was found to be the strongest genotype-derived predictor of
virological response and hence the most efficient representation of
the viral genotype with respect to therapy outcome.
We have used throughout two definitions of virological success
of treatment, namely reduction of viral load below 50 cps/ml and
below 400 cps/ml. The latter less stringent cutoff was included
because in the past it represented the limit of detection of viral
load assays. Today viral load values of 50 cps/ml and lower can
be measured and reduction below 50 cps/ml (or below the limit
of detection) is an accepted therapeutic goal. We generally found
very similar results for the two datasets, but the advantage of
using IGB over GSS (the de facto standard genotype interpre-
tation tool) reached statistical significance only for 400 cps/ml,
but not for 50 cps/ml. This finding may, in part, be due to the
larger dataset and hence increased statistical power for 400 cps/
ml as compared to 50 cps/ml. In the future, larger datasets will
be required to further evaluate the IGB and its potential to
predict treatment outcome without the need for expert rules. This
property of the IGB is particularly appealing for new drugs, for
which reliable rules are not readily available before evidence has
accumulated in published studies. Larger datasets and more
elaborate statistical variable importance methods [48] will also
increase the power to detect other factors of therapeutic outcome,
but the general consistency between the 50 cps/ml and 400 cps/
ml success definitions suggests that a sizable fraction of important
variables have been identified. In addition, larger TCE databases
will allow for analyzing alternative endpoints, such as time to
virological failure or virological response after a fixed period of
time.
In the univariate analysis, most drugs had a positive effect on
treatment outcome, with the exception of ZDV, d4T, 3TC, and
NFV. The negative associations might be due to the prominent
use of the drug combinations (ZDV or d4T) +3TC+ (IDV or
NFV), 90% of which were failures. The four drugs were among
the first to be approved for antiretroviral therapy and used in
early suboptimal regimens. Moreover, they were poorly
tolerated and therefore one can expect a general lower
adherence to treatment. A similar observation was made in
the multivariate analysis, where ZDV, ddI, SQV, 3TC and d4T
were significant predictors decreasing the odds of therapeutic
success. This effect might also be due to the common early use
of these drugs in mono therapy and their later use in salvage
regimens, even if multiple resistance mutations had already
accumulated [49]. Among PIs, a pronounced trend was that
boosting with RTV increased the odds of successful treatment.
The fraction of PI boosting in the dataset is reported in
Supporting Table S4.
A few variables did not show significant association with
therapy outcome although they might have been expected to. For
example, adherence is a well-known predictor of treatment
success [50,51], but it failed to reach significance in the
multivariate model, most likely due to lack of adherence data
for about 45% of the patients. The missing data resulted from
collecting adherence data within the SHCS only since January
2003. Indeed, in a multivariate analysis restricted to the subset of
1183 TCEs with observed adherence a more pronounced effect
can be observed. We have not included a set of variables in this
study that are known to be predictors because of the construction
of the dataset. The definition of the dataset of genotype-therapy
pairs allows for including several sequential TCEs from the same
patient. Most TCEs are actually derived from unique patients,
but some patients occur multiple times. Each TCE gives rise to
two therapy cases, a failure, which had given rise to the switch,
followed by a salvage regimen, which can be a failure or a
success. Therefore, we did not include variables that are affected
by the sequential ordering of therapies, such as the total time a
patient was under therapy with a certain drug or the calendar
year of treatment.
In summary, the IGB to regimen is a new predictor of treatment
outcome that captures, in a single quantity, the virus’ genetic
potential for developing drug resistance under the selective
pressure of the combination therapy. The IGB can be computed
efficiently for any viral genotype and any drug combination. It
may thus contribute to improved interpretation of genotypic drug
resistance tests and to the rational design of individualized
therapies. Future prospective studies are required to apply these
results to other patient populations and to eventually integrate
them into clinical practice.
Individualized Genetic Barrier
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Methods
Swiss HIV Cohort Study (SHCS) database
Founded in 1988, the SHCS is a nationwide, prospective,
multicenter, clinic-based cohort with continuous enrolment and
semi-annual study visits representing approximately 50% of all
HIV-infected and 75% of all treated patients in Switzerland [46].
The SHCS has been approved by ethical committees of all
participating institutions, and written informed consent has been
obtained from all participants. The SHCS drug resistance
database contains the results of 13,201 genotypic resistance tests
from 9,231 patients, stored in a central database [45]. Resistance
data stem from routine clinical testing (60%) and from tests
performed retrospectively from frozen repository plasma samples
(40%) (Table 1 and 2).
The SHCS has been approved by the following ethical
committees of all participating institutions: Kantonale Ethikkom-
mission Bern; Ethikkommission beider Basel; comite´ d’e´thique du
de´partement de me´dicine de Hoˆpitaux Universitaires de Gene´ve;
commission d’e´thique de la recherche clinique, Lausanne;
comitato etico cantonale, Bellinzona; Ethikkommission des
Kanton St.Gallens; and Ethik-Kommission Zu¨rich, all Switzer-
land. Written informed consent has been obtained from all
participants [46].
Treatment change Episode (TCE) data
TCEs were obtained from the SHCS database as follows. Each
TCE consists of a failing therapy followed by a salvage therapy
(Supporting Figure S1). We required that the failing therapy was at
least four month long and that the genotype was measured no
more than 90 days before and no more than 30 days after onset of
the uninterrupted salvage therapy [26]. In order to restrict to
failing regimens due to viral rebound and to exclude convenience
treatment changes or single determinations of low-level viremias
(blips), a failing therapy was defined by either two consecutive viral
load measurements above 500 cps/ml, or a single viral rebound
followed by therapy switch, or single rebound after 180 days and
lack of viral suppression below the limit of detection.
Therapies were labeled ‘success’ versus ‘failure’ as follows. Any
failing therapy was considered a failure. Salvage therapies were
considered successful, if viral load dropped below 50 cps/ml at
any time point during treatment, otherwise they were considered
failures. Because viral load assays with a sensitivity of 50 cps/ml
were not available for the whole observation period, we also
considered an alternative definition of therapy success as a viral
load reduction below 400 cps/ml. The TCE dataset spans the
time period 1988–2010, but 75% of TCEs date from 2000 or later.
Isotonic Conjunctive Bayesian Network (I-CBN) models
Genetic progression of the virus under selective drug pressure
and the resulting phenotypic drug resistance changes were
modeled jointly using I-CBNs [44]. In this model, mutations
occur subject to partial order constraints which define the
genotype lattice, the set of genotypes compatible with the
constraints, and drug resistance is non-decreasing along any
mutational pathway (Figure 1). Formally (see [44] for details), let
(E,[) be a partially ordered set of n mutations. Each genotype is
identified with the subset g(E of mutations it carries. The
genotype lattice G induced by (E,[) is the set of all genotypes g for
which it holds that e[g implies e’[g whenever e’[e in E. We
denote by Exit[(g) the set of accessible mutations from genotype
g under the given partial order constraints. The I-CBN is a
statistical model for the random variables X[2E^f0,1gn,
describing observed genotypes, and Y[R, describing associated
drug resistance phenotypes, both of which are observed from true
hidden genotypes Z[G(2E subject to noise. The probability of an
unobserved genotype Z is defined as
P(Z~g)~ P
e[g
he: P
e[Exit[(g)
(1{he) ð1Þ
where the parameters he denote the conditional probabilities of
mutation e[E given that all of its predecessor mutations have
occurred, he~P e[ZjVe0[Z, e0ve, e0=eð Þ. The observed random
variables X and Y are independent given Z. The genotype
observation error is modeled as
P(X DZ)~(1{e)n{d(X ,Z)ed(X ,Z) ð2Þ
where d denotes the Hamming distance and errors are assumed to
occur independently among sites at rate e. The observed drug
resistance phenotype Y is the log fold-change in susceptibility. For
each genotype Z, it follows a normal distribution
P(Y DZ)~Norm(mZ, s) ð3Þ
subject to the monotonicity contraints mgƒmh for all genotypes
g(h. The complete model for X and Y is then the marginal-
ization
P(X ,Y )~
X
Z
P(Z)P(X DZ)P(Y DZ) ð4Þ
Parameter estimation for this model was performed using the EM
algorithm described in [44].
The model was applied separately to 18 antiretroviral drugs,
using between 280 and 2303 (median 1448) cross-sectional
genotype-phenotype pairs, i.e., observations of (X ,Y ), obtained
from the Stanford HIV Drug Resistance Database, restricted to
subtype B sequences and to Phenosense or Antivirogram assays
[52]. For each drug, we selected its resistance-associated mutations
reported on the Stanford HIVdb website lumping together
mutations occurring at the same site, or if unavailable, applied
L1-penalized (lasso) linear regression [53,54] to select from all PR or
RT mutations occurring at least ten times a sparse set E of n~10
predictor mutations. The performance of the models is reported as
the Pearson correlation coefficient between true and predicted
phenotypes, estimated from a separate, random subset of 20% of the
data. Phenotypic cutoff values were derived from the distribution of
fold-change values as described previously [15,26] and used to
dichotomize resistance predictions (Supporting Table S2).
Individualized Genetic Barrier (IGB)
Given an I-CBN model, transition probabilities among geno-
types g, h[G can be computed as
P(g?h)~ P
e[h\g
he: P
e[Exit[(g)\h
(1{he) ð5Þ
Using these transition probabilities and the predicted drug
resistance phenotypes mg, we define the IGB of genotype g[G to
resistance to drug d as the probability of the virus not reaching any
genotypic state predicted as resistant,
IGBd (g)~1{
X
h[Gd
P(g?h) ð6Þ
Individualized Genetic Barrier
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where Gd5G is the subset of all genotypes g predicted to be
resistant to drug d , i.e., for which mg is greater than the resistance
cutoff (Supporting Table S2).
Genotypes outside the lattice G (not complying with the partial
order constraints) are regarded as erroneous observations of the
genotypes in the lattice. The IGB of such a genotype f is
IGBd (f )~1{
X
g[G
P(gDf ) 1{IGBd (g)½  ð7Þ
where P(gDf ) is the probability of the actual genotype being g
given that f has been observed. By Bayes’ theorem,
P(gDf )~
P(f Dg)P(g)P
h[G P(f Dh)P(h)
ð8Þ
where P(f Dg)~(1{e)n{d(f ,g)ed(f ,g) is modeled as in Eq. 2.
The genetic barrier to escape from a regimen R is defined as the
sum of the drug-specific barriers over all drugs in the regimen
IGBR(g)~
X
d[R
IGBd (g) ð9Þ
Because the IGB to each drug can be regarded as an estimate of
the activity of the drug (the probability of not escaping), the IGB to
a regimen may be interpreted as the expected number of active
drugs in the regimen. Note that 0ƒIGBR(g)ƒDRD, that
IGBR(g)&0 means that evolutionary escape is almost certain,
and that adding a drug to a regimen can only increase the genetic
barrier to the regimen.
Statistical analysis
For classifying therapies as failures versus successes, univariate,
multivariate, and regularized multivariate logistic regression was
used. For a set of precitors x1, . . . ,xm, the therapeutic success
probability p is modeled by the regression
log
p
1{p
 
~b0zb1x1z . . .zbmxm ð10Þ
where bj are the regression coefficients. The odds ratio of
therapeutic success associated with a one-unit increase in predictor
j is ebj . P-values for the predictors are corrected for multiple testing
using the Benjamini-Hochberg procedure. For regularization, we
applied the elastic net [55], which combines an L1 (lasso) penalty
encouraging sparse solutions with an L2 (ridge) penalty that tends to
average across correlated features. Classifier performance was
evaluated using ROC curves and is reported as the area under the
ROC curve (AUC). The data was ten times randomly split into 40%
for estimation of the two hyperparameters (one for the degree of
each type of regularization) and 60% for model fitting and testing,
which was done by 10-fold cross-validation [56].
The R language for statistical computing (http://www.r-project.
org/) was used for all analyses, including the R packages icbn,
glmnet, and ROCR. An R script for computing the IGB is
available at: http://www.cbg.ethz.ch/software/igb. The Stanford
HIVDB Sierra web service was used for GSS computation.
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Supporting Information
Figure S1 Treatment change episode (TCE). Each TCE
consists of a failing therapy followed by a salvage therapy. The
failing therapy gives rise to a failure, whereas the salvage therapy
can be either a success or a failure, depending on whether viral
load suppression below 50 cps/ml (400 cps/ml) was achieved
during treatment or not (see Methods). Genotypes are measured
prior to or at the beginning of the salvage regimen. Examples of
successful salvage therapy and failing salvage therapy are given in
part (A) and (B) of this figure, respectively.
(EPS)
Figure S2 Drug usage in the SHCS database. Drug
frequencies among successful (green) and failing (red) regimens
for the TCEs of the SHCS database. Successful treatment was
defined as a reduction in viral load below 50 cps/ml (A) or
400 cps/ml (B).
(EPS)
Figure S3 Most abundant drug combinations in the
SHCS database. Frequencies of the 30 most abundant drug
combinations in the SHCS database. Successful treatment was
defined as a reduction in viral load below 50 cps/ml (A) or
400 cps/ml (B).
(EPS)
Figure S4 I-CBN model for resistance development to
ZDV. Partially ordered set of RT mutations 41L, 67N, 70R, 74I,
74V, 184V, 210W, 215F, 215Y, 219Q associated with resistance
to ZDV (A) and induced genotype lattice (B). Genotypes are
colored green if predicted susceptible and red if predicted resistant.
(EPS)
Figure S5 I-CBN model for resistance development to
DDI. Partially ordered set of RT mutations 41L, 65R, 69Ins,
74VI, 151M, 184VI, 210W, 215FY associated with resistance
to DDI (A) and induced genotype lattice (B). Genotypes are
colored green if predicted susceptible and red if predicted
resistant.
(EPS)
Figure S6 I-CBN model for resistance development to
DDC. Partially ordered set of RT mutations 41L, 65R, 67N,
75M, 75T, 116Y, 151M, 184V, 210W, 211N associated with
resistance to DDC (A) and induced genotype lattice (B). Genotypes
Individualized Genetic Barrier
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are colored green if predicted susceptible and red if predicted
resistant.
(EPS)
Figure S7 I-CBN model for resistance development to
D4T. Partially ordered set of RT mutations 41L, 65R, 67N,
69Ins, 70R, 151M, 184VI, 210W, 215FY, 219QE associated with
resistance to D4T (A) and induced genotype lattice (B). Genotypes
are colored green if predicted susceptible and red if predicted
resistant.
(EPS)
Figure S8 I-CBN model for resistance development to
3TC. Partially ordered set of RT mutations 41L, 67N, 70R,
181C, 184V, 190A, 210W, 215F, 215Y, 219Q associated with
resistance to 3TC (A) and induced genotype lattice (B). Genotypes
are colored green if predicted susceptible and red if predicted
resistant.
(EPS)
Figure S9 I-CBN model for resistance development to
ABC. Partially ordered set of RT mutations 41L, 65R, 69Ins,
74VI, 115F, 151M, 184VI, 210W, 215FY associated with
resistance to ABC (A) and induced genotype lattice (B). Genotypes
are colored green if predicted susceptible and red if predicted
resistant.
(EPS)
Figure S10 I-CBN model for resistance development to
TDF. Partially ordered set of RT mutations 41L, 65R, 69Ins,
70R, 74VI, 115F, 151M, 184VI, 210W, 215FY associated with
resistance to TDF (A) and induced genotype lattice (B). Genotypes
are colored green if predicted susceptible and red if predicted
resistant.
(EPS)
Figure S11 I-CBN model for resistance development to
FTC. Partially ordered set of RT mutations 65R, 69Ins, 151M,
184VI associated with resistance to FTC (A) and induced genotype
lattice (B). Genotypes are colored green if predicted susceptible
and red if predicted resistant.
(EPS)
Figure S12 I-CBN model for resistance development to
EFV. Partially ordered set of RT mutations 100I, 101EP, 103NS,
106AM, 181CIV, 188LHC, 190ASE, 230L associated with
resistance to EFV (A) and induced genotype lattice (B). Genotypes
are colored green if predicted susceptible and red if predicted
resistant.
(EPS)
Figure S13 I-CBN model for resistance development to
NVP. Partially ordered set of RT mutations 100I, 101EP, 103NS,
106AM, 181CIV, 188LHC, 190ASE, 230L associated with
resistance to NVP (A) and induced genotype lattice (B). Genotypes
are colored green if predicted susceptible and red if predicted
resistant.
(EPS)
Figure S14 I-CBN model for resistance development to
RTV. Partially ordered set of PR mutations 24I, 30N, 32I, 46I,
46L, 54V, 73S, 82A, 84V, 90M associated with resistance to RTV
(A) and induced genotype lattice (B). Genotypes are colored green
if predicted susceptible and red if predicted resistant.
(EPS)
Figure S15 I-CBN model for resistance development to
SQV. Partially ordered set of PR mutations 48VM, 54VTALM,
82AT, 84V, 88S, 90M associated with resistance to SQV (A) and
induced genotype lattice (B). Genotypes are colored green if
predicted susceptible and red if predicted resistant.
(EPS)
Figure S16 I-CBN model for resistance development to
IDV. Partially ordered set of PR mutations 32I, 46IL, 47V,
54VTALM, 76V, 82AFTS, 84V, 88S, 90M associated with
resistance to IDV (A) and induced genotype lattice (B). Genotypes
are colored green if predicted susceptible and red if predicted
resistant.
(EPS)
Figure S17 I-CBN model for resistance development to
NFV. Partially ordered set of PR mutations 30N, 46IL, 47V,
48VM, 54VTALM, 82AFTS, 84V, 88DS, 90M associated with
resistance to NFV (A) and induced genotype lattice (B). Genotypes
are colored green if predicted susceptible and red if predicted
resistant.
(EPS)
Figure S18 I-CBN model for resistance development to
LPV. Partially ordered set of PR mutations 32I, 46IL, 47VA,
48VM, 50V, 54VTALM, 76V, 82AFTS, 84V, 90M associated
with resistance to LPV (A) and induced genotype lattice (B).
Genotypes are colored green if predicted susceptible and red if
predicted resistant.
(EPS)
Figure S19 I-CBN model for resistance development to
APV. Partially ordered set of PR mutations 24I, 32I, 46I, 46L,
48V, 53L, 54V, 82A, 84V, 90M associated with resistance to APV
(A) and induced genotype lattice (B). Genotypes are colored green
if predicted susceptible and red if predicted resistant.
(EPS)
Figure S20 I-CBN model for resistance development to
ATV. Partially ordered set of PR mutations 10I, 32I, 33F, 46I,
48V, 54V, 71V, 82A, 84V, 90M associated with resistance to ATV
(A) and induced genotype lattice (B). Genotypes are colored green
if predicted susceptible and red if predicted resistant.
(EPS)
Figure S21 I-CBN model for resistance development to
TPV. Partially ordered set of PR mutations 32I, 46IL, 47VA,
54VAM, 82TL, 84V associated with resistance to TPV (A) and
induced genotype lattice (B). Genotypes are colored green if
predicted susceptible and red if predicted resistant.
(EPS)
Figure S22 Univariate analysis of predictors of re-
sponse to antiretroviral combination therapy in the
SHCS database. Associations have been tested using logistic
regression models and odds ratios of therapeutic success, defined
as viral load reduction below 50cps/ml (A) and 400cps/ml (B), are
reported together with their 95% confidence intervals on a
logarithmic scale. Benjamini-Hochberg-corrected p-values are
represented as black (pv0:001) and grey (pv0:01) symbols. Only
predictors with a p-value smaller than 0.01 are included.
(EPS)
Table S1 Complete list of all variables analyzed with
respect to treatment outcome. Groups NRTI, NNRTI, and
PI consist of binary variables, one for each drug, indicating the
presence of the respective drug in the regimen. For PIs, boosted
(given together with low-dose RTV) and unboosted formulations
are distinguished, except for LPV which is always applied boosted.
The variable RTV refers to the use of ritonavir as the only PI in
the regimen. Demographic and clinical variables include age and
Individualized Genetic Barrier
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gender of the patient, whether he or she had AIDS, the maximum
viral load and the minimum CD4 T cell count measured anytime
before treatment onset, transmission group (BLOOD, HET, IDU,
MSM, or OTHER), and adherence. Patient adherence was
assessed in questionnaires and measured as the percentage of
missed dosages [50,51] for 1183 (45%) of the patients, and then
dichotomized. For the multivariate analysis only, unobserved
values of patient adherence were imputed by a logistic regression
model (one for each dataset) from all remaining variables except
the response (treatment outcome). For each drug, the individual-
ized genetic barrier (IGB) is the probability of the virus not
escaping from the selective pressure of the drug. The IGB to
regimen is defined as the sum of the drug-specific IGBs over all
drugs in the regimen. Mutations in the PR and RT of HIV-1 are
denoted by the sequence position followed by the amino acid.
Each variable is binary indicating the presence of the respective
amino acid at the respective position in the protein. Only
mutations that occurred in at least 5% of the samples are
considered.
(PDF)
Table S2 Construction of I-CBN models. For each drug, is
reported the number N of genotype-phenotype pairs the model
has been learned from, the correlation coefficient R between
predicted and true drug resistance phenotypes, the list of selected
mutations, and the cutoff value C defining resistant versus
susceptible viruses. The correlation coefficient has been estimated
from an independent test set consisting of 20% of the data that was
not used for training. For ZDV, DDI, D4T, 3TC, ABC, TDF,
FTC, EFV, NVP, SQV, IDV, NFV, LPV, and TPV, the
corresponding drug resistance-associated mutations reported on
the Stanford HIV Drug Resistance Database website were used,
while for DDC, RTV, APV, and ATV, we selected ten mutations
using L1-penalized linear regression (lasso).
(PDF)
Table S3 Different categories of drug combinations in
SHCS databse. The first category includes drug combinations
currently recommended as first-line or alternative regimens
according to the JAMA recommendations [42]. Category 2
includes regimens that were recommended as first-line or
second-line regimens in the past, regimens that are still in use in
developing countries or are used sometimes if drug resistant virus
is present at baseline, or salvage regimens. Category 3 includes
older regimens that are not in use anymore as first-line regimens
but were before, regimens that are not corresponding to
guidelines, including those that are sometimes used in special
circumstances, such as unusual tolerability, etc. To evaluate the
prediction performance (sensitivity and specificity) of each
category, leave-one-out cross-validation experiments were per-
formed.
(PDF)
Table S4 PI usage and boosting fraction. Reported is the
total number of regimens in the SHCS database that include the
respective PI, and in parenthesis, the percentage that the PI is
boosted, i.e., given together with low-dose ritonavir (RTV).
(PDF)
Table S5 Comparative performance in predicting treat-
ment outcome, defined as a reduction of viral load below
50cps/ml, for different elastic net regularized logistic
regression models. Comparative performance in predicting
treatment outcome, defined as a reduction of viral load below
50cps/ml, for different elastic net regularized logistic regression
models. In columns 3–8, the p-value of a two-sided Wilcoxon rank
sum test for differences in the area under the ROC curve (AUC;
column 2) is reported. Prediction models (column 1) are encoded
by the sets of predictors used, where C refers to the demographic
and clinical variables, D refers to drugs, and M to mutations. For
example, the model IGB+CDM includes as predictors IGB to
regimen, clinical and demographic predictors, applied drugs, and
mutations.
(PDF)
Table S6 Comparative performance in predicting treat-
ment outcome, defined as a reduction of viral load below
400cps/ml, for different elastic net regularized logistic
regression models. Comparative performance in predicting
treatment outcome, defined as a reduction of viral load below
400cps/ml, for different elastic net regularized logistic regression
models. In columns 3–8, the p-value of a two-sided Wilcoxon rank
sum test for differences in the area under the ROC curve (AUC;
column 2) is reported. Prediction models (column 1) are encoded
by the sets of predictors used, where C refers to the demographic
and clinical variables, D refers to drugs, and M to mutations. For
example, the model IGB+CDM includes as predictors IGB to
regimen, clinical and demographic predictors, applied drugs, and
mutations.
(PDF)
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